Cyklokapron

Antifibrinolytic hemostatic used in severe hemorrhage. .
[PubChem].

Cyklokapron - Pharmacology:

Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.

Cyklokapron mini report

Cyklokapron NDA
NDA - A product marketed under an approved New Drug Application
Cyklokapron INJECTION, SOLUTION
INJECTION, SOLUTION
Cyklokapron HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Start - Stop data
START DATA:
1986-Dec-30
Start - Stop data
STOP DATA
not occurred

Cyklokapron Interactions

No information provided.

Cyklokapron Contraindications

CYKLOKAPRON Tablets and Injection are contraindicated:

  1. In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity.
  2. In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
  3. In patients with active intravascular clotting.

Cyklokapron tags categories:

Generic name, Overdose, Half Life Cyklokapron, Food Interactions, Chemical, etc..

Cyklokapron see also FDA report

Brand Names containing Tranexamic Acid
Surgery